Clearpoint Neuro, INC 8-K filings

ClearPoint Neuro, Inc. held its annual stockholder meeting on May 20, 2026, where shareholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan and ratified the appointment of Cherry Bekaert LLP as auditors.

ClearPoint Neuro announced record full-year 2025 revenue of $37.0 million, up 18%, driven by strong organic growth and the IRRAS Holdings acquisition, with 2026 revenue projected between $52.0M and $56.0M.

ClearPoint Neuro, Inc. has filed an amendment to its 8-K, providing historical financial statements for the recently acquired IRRAS Holdings, Inc. and pro forma combined financial information.

ClearPoint Neuro announced preliminary unaudited fourth quarter 2025 revenue of $10.4 million, marking 20% comparable sales growth, and projected 2026 revenues between $54 million and $60 million.

ClearPoint Neuro, Inc. announced an internal reorganization of its Swedish subsidiary, IRRAS AB, to qualify it as an Immaterial Foreign Subsidiary under its Note Purchase Agreement.

ClearPoint Neuro, Inc. has finalized its acquisition of IRRAS Holdings, Inc., expanding its neurocritical care and drug delivery portfolio.

ClearPoint Neuro, Inc. announced a 9% revenue increase in Q3 2025, reaffirmed full-year guidance, and detailed strategic advancements including a key acquisition and new product clearances.

ClearPoint Neuro, Inc. announced the acquisition of IRRAS Holdings, Inc., a medical technology company, to expand its neurocritical care and drug delivery portfolio.

ClearPoint Neuro, Inc. announced record second-quarter 2025 revenue of $9.2 million, a 17% year-over-year increase, alongside a significant $105.0 million note financing arrangement.

ClearPoint Neuro, Inc. has entered into a new lease agreement for approximately 30,171 square feet of life science space in San Diego, California, signaling a significant expansion of its office, research and development, and laboratory capabilities.

ClearPoint Neuro, Inc. announced that its stockholders approved all six proposals at the annual meeting, including the adoption of a new incentive compensation plan, the re-election of directors, and the ratification of its independent auditor.

ClearPoint Neuro updates its Non-Employee Director Compensation Plan to enhance its ability to attract and retain qualified board members.

ClearPoint Neuro announces record first-quarter revenue of $8.5 million, driven by a 70% increase in single-use navigation and therapy products.

ClearPoint Neuro announces a significant financing agreement with Oberland Capital, including a note financing arrangement of up to $105 million and a $3.5 million registered direct offering.

ClearPoint Neuro achieved record revenue of $31.4 million in 2024, a 31% increase year-over-year, and reduced operational cash burn by 35%.

ClearPoint Neuro has entered into an agreement to sell up to $50 million of its common stock through an at-the-market offering program.

ClearPoint Neuro reported record revenue and a significant reduction in operational cash burn for the third quarter of 2024, driven by strong growth in its navigation and therapy product lines.

ClearPoint Neuro has fully repaid a $10 million convertible note ahead of its maturity, eliminating all debt from its balance sheet.

ClearPoint Neuro reported a 32% year-over-year revenue increase in the second quarter of 2024, driven by strong product sales and strategic growth initiatives, leading to an increased full-year revenue guidance.

ClearPoint Neuro's stockholders approved the Fifth Amended and Restated 2013 Incentive Compensation Plan and elected eight directors at their annual meeting on May 15, 2024.

ClearPoint Neuro announced a 41% year-over-year increase in revenue for the first quarter of 2024, reaching a record $7.6 million.

ClearPoint Neuro announced a 32% year-over-year revenue increase for the fourth quarter of 2023 and a 17% increase for the full year, alongside key operational achievements and a reaffirmed 2024 revenue guidance.

ClearPoint Neuro has entered into an underwriting agreement for a public offering of 2,307,694 shares of common stock at $6.50 per share, potentially raising up to $16.2 million if the underwriter's option is fully exercised.